Psychiatrie (178)
Podřazené kategorie
Přehledné články
Pavel Mohr, Mabel Rodriguez, Anna Slavíčková, Jan Hanka
Stimulační metody v terapii deprese: využití vagové stimulace (VNS)
a hluboké mozkové stimulace (DBS) .....................................................................................130
Jiří Patočka, Kamil Kuča
Syntetické kannabinoidy a „spice drugs" ...............................................................................140
Miloslava Raisová, Miloslav Kopeček, Daniela Řípová, Aleš Bartoš
Addenbrookský kognitivní test a jeho možnosti použití v lékařské praxi ....................................145
Fórum české neuropsychofarmakologické společnosti
Jaromír Švestka, Pavel Mohr
Nová antipsychotika: Lurasidon .............................................................................................160
CONTENTS
Editorial.... ...........................................................................................................................120Reviews
Pavel Mohr, Mabel Rodriguez, Anna Slavíčková, Jan Hanka
Stimulatory methods in treatment of depression: the use of nerve vagus
stimulation (VNS) and deep brain stimulation (DBS) .................................................................130
Jiří Patočka, Kamil Kuča
Synthetic cannabinoids and „spice drugs" ...............................................................................140
Miloslava Raisová, Miloslav Kopeček, Daniela Řípová, Aleš Bartoš
Addenbrooke's cognitive examination and its potential use in medical practice ............................145
Forum of the czech neuropsychopharmacological society
Jaromír Švestka, Pavel Mohr
New Antipsychotics: Lurasidone .............................................................................................160
FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI
Pavel Mohr, Jan Volavka
Adherence a depotní antipsychotika v léčbě schizofrenie....................................................... 104
Přečetli jsme za vás........................................................................................................... 113
Nové knihy......................................................................................................................... 115
Informace........................................................................................................................... 116
CONTENTS
EDITORIAL ...........................................................................................................................61FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY
Pavel Mohr, Jan Volavka
Adherence and depot formulations of antipsychotics in schizophrenia.......................................104
We have read for you ...........................................................................................................113
New Books......................................................................................................................... 115
Informations........................................................................................................................ 116
Pùvodní práce
Přehledné články
Kazuistiky
Vzdělávání
Fórum České neuropsychofarmakologické společnosti
CONTENT
Original Papers
Reviews
Case Report
CME
Forum of the czech neuropsychopharmacological society
KRÁTKÁ SDĚLENÍ
str. 3-34
str. 34-67
str. 68-101
str. 102-122
str. 123-152
SHORT COMMUNICATIONS
p. 3-34
p. 34-67
p. 68-101
p. 102-122
p. 123-152
EDITORIAL ...................................................................................................................... 90
PÙVODNÍ PRÁCE
C. Škoda, P. Baudiš, T. Dostal, E. Dragomirecká, E. Johanovská, H. Papežová,
H. Svatoňová, D. Taussigová:
Mezinárodní studie schizofrenie koordinovaná Svìtovou zdravotnickou
organizací (ISoS) - III. Použité vyšetřovací nástroje a komunikaèní postupy............................. 92
I. Mazura, R. Jirák, F. Koukolík:
Molekulárnì genetická analýza Alzheimerovy demence
v èeské populaci II ............................................................................................................. 96
J. Horáček:
Deprese českého šlechtice v polovině XVI. století (Z pamětí Jana Zajíce z Házmburka) ............ 99
PŘEHLEDNÉ ČLÁNKY
F. Koukolík:
Prefrontální - subkortikální systémy ................................................................................... 102
C. Höschl:
Biologická psychiatrie roku 2000 ...................................................................................... 107
Z. Klein:
Sexuální obtěžování z pohledu etologie člověka ................................................................... 117
J. Horáček, M. Kuzmiaková:
Je deprese poruchou inzulinových receptorù? ...................................................................... 121
L. Motlová:
Psychoedukce u schizofrenie ............................................................................................. 127
P. Entnerová, J. Bouček:
Psychické reakce na závažný stres - záplavy ..................................................................... 130
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová antidepresiva: SNRI ................................................................................................. 135
KRÁTKÁ SDĚLENÍ ........................................................................................................ 139
ZPRÁVY ........................................................................................................................ 140
Přečetli jsme za Vás ...................................................................................................... 144
DOPISY, DISKUSE A OHLASY ....................................................................................... 147
NOVÉ KNIHY .................................................................................................................. 149
INFORMACE ................................................................................................................. 152
CONTENTS
EDITORIAL .................................................................................................................... 90
ORIGINAL PAPERS
C. Škoda, P. Baudiš, T. Dostal, E. Dragomirecká, E. Johanovská, H. Papežová,
H. Svatoňová, D. Taussigová:
WHO coordinated International Study of Schizophrenia - ISoS
III. Applied Schedules and Logistics ................................................................................. 92
I. Mazura, R. Jirák, F. Koukolík:
Molecular-Genetic Analysis of Alzheimer's Dementia in Czech Population II ........................ 96
J. Horáèek:
The Depression of Czech Nobleman in the Middle of 16th Century
from Memoirs of Jan Zajíc of Házmburk ........................................................................... 99
REVIEWS
F. Koukolík:
Prefrontal - subcortical Circuits ..................................................................................... 102
C. Höschl:
Biological Psychiatry in the Year 2000 ........................................................................... 107
Z. Klein:
The Phenomenon of Sexual Harassment from the Point
of View of Human Ethology ............................................................................................ 117
J. Horáèek, M. Kuzmiaková:
Is Depression the Disorder of Insulin Receptors? .............................................................. 121
L. Motlová:
Psychoeducation in schizophrenia .................................................................................. 127
P. Entnerová, J. Bouèek:
Psychic Reactions to Serious Stress: Deluges in Summer 1997
in Czech Republic .......................................................................................................... 130
NEW PSYCHOTROPICS
J. Švestka:
New Antidepressants: SNRI ........................................................................................... 135
BRIEF ARTICLES ......................................................................................................... 139
COMMUNICATIONS ..................................................................................................... 140
We have read for you ..................................................................................................... 144
CORRESPONDENCE, DISCUSSION............................................................................... 147
NEW BOOKS ................................................................................................................ 149
INFORMATION .............................................................................................................. 152
EDITORIAL ....................................................................................................... 38
PŮVODNÍ PRÁCE
E. Růžička:
Extrapyramidové poruchy v neurologii a psychiatrii ...................................... 40
L. Velíšek:
Jak modelovat psychomotorické záchvaty? ........................................................ 47
M. Matoušek, A. Edman:
Vztah mezi sníženou vigilitou a projevy demence ........................................... 52
C. Škoda, P. Baudiš, T. Dostal, E. Dragomirecká, E. Johanovská, H. Papežová,
H. Svatoňová, D. Taussigová:
Mezinárodní studie schizofrenie koordinovaná Světovou zdravotnickou
organizací (ISoS) - II. Výsledky vyhledávání, ztráty .......................................... 56
I. Mazura, F. Koukolík, R. Jirák:
Molekulárnì genetická analýza Alzheimerovy
demence v èeské populaci I .................................................................................... 62
J. Praško, P. Baudiš, J. Klaschka:
Fototerapie v léčbě rekurentních unipolárních depresí. ................................ 65
PŘEHLEDNÉ ČLÁNKY
J. Šípek:
Principy KBT v ságách z úsvitu dìjin .................................................................. 70
Z. Matějček:
Typologie následků psychické deprivace ............................................................ 72
R. Balon:
Kulty z hlediska psychiatrie ................................................................................... 76
ZPRÁVY ............................................................................................................... 78
Přečetli jsme za vás ................................................................................................... 84
NOVÉ KNIHY ................................................................................................... 85
INFORMACE ..................................................................................................... 86
CONTENTS
EDITORIAL ....................................................................................................... 38
ORIGINAL PAPERS
E. Růžička:
Extrapyramidal Disorders in Neurology and Psychiatry ................................ 40
L. Velíšek:
How to Model Psychomotor Seizures? ................................................................ 47
M. Matoušek, A. Edman:
Relationship Between Lower Alertness Level and Symptoms of
Dementia..................................................................................................................... 52
C. Škoda, P. Baudiš, T. Dostal, E. Dragomirecká, E. Johanovská, H. Papežová,
H. Svatoňová, D. Taussigová:
WHO Coordinated International Study of Schizophrenia
II. Results of Tracing, Drop Outs ......................................................................... 56
I. Mazura, F. Koukolík, R. Jirák:
Molecular-Genetic Analysis of Alzheimer's Dementia in Czech
Population I: the Variability of Apolipoprotein E /Apo E/ ........................... 62
J. Praško, P. Baudiš, J. Klaschka:
Phototherapy in the Treatment of Reccurent Unipolar Depression .................................. 65
REVIEWS
J. Šípek:
Cognitive Behavioral Principles in Ancient Sagas ............................................ 70
Z. Matějček:
Typology of Psychic Deprivation Sequelae ........................................................ 72
R. Balon:
Cults in Psychiatric View ........................................................................................ 76
COMMUNICATIONS ......................................................................................... 78
We have read for you ................................................................................................ 84
NEW BOOKS ............................................................................................................ 85
INFORMATION ..................................................................................................... 86
EDITORIAL ................................................................................................................... 212
PŮVODNÍ PRÁCE
S. Kapur: Co nám říkají zobrazovací receptorové studie o léčbě schizofrenie? ..................... 213
L. Kubièka, Z. Dytrych, Z. Matìjèek, Z. Roth:
Prediktabilita psychosociálních charakteristik dospělých lidí na základì IQ
a osobnostních rysù zjištěných v dětském věku ............................................................... 216
Z. Klein, Z. Dáňová, P. Nepivoda, V. Peřina:
Dermatoglyfy rukou èeské populace - I. prstové vzory .........................................................223
PŘEHLEDNÉ ČLÁNKY
M. Valchář: Genetika a nemoci CNS ............................................................................... 231
J. Gut: Enuresis Nocturna - současné pohledy ................................................................ 238
KAZUISTIKY
M. Kolomazník, J. Hronek, J. Kolomazník, P. Kufner:
Sertralin v léčbě ejaculatio praecox: Intermitentnì nebo kontinuálnì? Příspěvek
k poznání mechanizmu účinku serotonergních preparátù ................................................... 244
O. Lang: Mýtus a psychoterapia.
Význam symbolov a mýtov v K.I.P. ................................................................................. 247
NOVÁ PSYCHOFARMAKA
J. Švestka: Antiepileptika III. generace a jejich použití v psychiatrii ................................ 250
ZPRÁVY ....................................................................................................................... 263
Přečetli jsme za Vás ......................................................................................................275
DOPISY, DISKUZE A OHLASY ..................................................................................... 283
NOVÉ KNIHY ............................................................................................................. 288
INFORMACE................................................................................................................ 290
CONTENTS
EDITORIAL ................................................................................................................... 212
ORIGINAL PAPERS
S. Kapur: What Receptor Imaging Studies Tell Us
About the Treatment of Schizophrenia? ........................................................................... 213
L. Kubička, Z. Dytrych, Z. Matějček, Z. Roth:
The Predictability of Adult Individuals' Psychosocial
Characteristics on the Basis of IQ and Personality
Traits Assessed in Childhood ......................................................................................... 216
Z. Klein, Z. Dáòová, P. Nepivoda, V. Peøina:
Dermatoglyphics of Hands in Czech Population
I. Fingertip Patterns .......................................................................................................223
REVIEWS
M. Valchář: Genetics and CNS Diseases ....................................................................... 231
J. Gut: Nocturnal Enuresis - Recent Opinions ................................................................ 238
CASE REPORTS
M. Kolomazník, J. Hronek, J. Kolomazník, P. Kufner:
Treatment of Premature Ejaculation with Sertraline:
Intermitently or Continuously? A Contribution
to Understanding the Mode of Action of Serotonergic Drugs ............................................. 244
O. Lang: Myth and Psychotherapy. Meaning of Symbols
and Myths in K.I.P. ....................................................................................................247
NEW PSYCHOTROPICS
J. Švestka: Anticonvulsants of the 3rd Generation in Psychiatry ...................................250
COMMUNICATIONS .............................................................................................. 263
We have read for you ............................................................................................. 275
CORRESPONDENCE, DISCUSSION....................................................................... 283
NEW BOOKS........................................................................................................ 288
INFORMATION........................................................................................................ 290
EDITORIAL ......................................................................................................... 152
PÙVODNÍ PRÁCE
M. Maršálek:
Mentální aspekty polékových extrapyramidových poruch .......................................... 154
J. Horáček, L. Motlová, J. Libiger, R. Bahbouh:
D-fenfluraminový test: sonda serotoninergní neurotransmise..................................... 159
P. Weiss, J. Zvěřina:
Mimomanželské suxuální styky u obyvatel České republiky .................................... 164
KAZUISTIKY
V. Borecký:
Jan Lukeš .......................................................................................................... 167
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová psychofarmaka: Sertindol .............................................................................. 174
ZPRÁVY .............................................................................................................. 181
Přečetli jsme za Vás ............................................................................................ 197
DOPISY, DISKUZE A OHLASY ............................................................................ 202
NOVÉ KNIHY ...................................................................................................... 206
INFORMACE....................................................................................................... 208
EDITORIAL ........................................................................................................ 152
ORIGINAL PAPERS
M. Maršálek:
Mental Aspects of Drug-Induced Extrapyramidal Disorders .................................... 154
J. Horáček, L. Motlová, J. Libiger, R. Bahbouh:
D-Fenfluramine Challenge Test - The Probe for Serotoninergic Neurotransmission .....159
P. Weiss, J. Zvěřina:
Extramarital Sex in the Czech Republic:
Results of a National Survey ............................................................................... 164
CASE REPORTS
V. Borecký:
Jan Lukeš ........................................................................................................... 167
NEW PSYCHOTROPICS
J. Švestka:
New Antipsychotics: Sertindol ............................................................................... 174
COMMUNICATIONS ............................................................................................. 181
We have read for you ............................................................................................ 197
CORRESPONDENCE, DISCUSSION .................................................................... 202
NEW BOOKS....................................................................................................... 206
INFORMATION .................................................................................................... 208
EDITORIAL ........................................................................................................... 62
PŮVODNÍ PRÁCE
J. Libiger, J. Švestka a český tým hodnotitelù studie:
Olanzapin verzus haloperidol: Výsledky akutní fáze dvojitì slepé
studie úèinnosti nového atypického neuroleptika u pacientù se
schizofrenní a schizoafektivní psychózou.............................................................. 64
J. Židovská, Š. Růžičková, M. Vojtíšková, E. Havrdová, J. Roth, J. Kapras:
DNA analýza genu Huntingtonovy choroby v české populaci .................................. 70
J. Bečka, E. Nagyová, J. Horáček:
Charakteristiky snù u vybraných duševních onemocnění .......................................... 74
PŘEHLEDNÉ ČLÁNKY
C. Höschl: Teorie deprese ................................................................................... 78
M. Alda: Co nového v genetickém výzkumu maniodepresivity? ................................ 86
P. Mohr: Deficitní syndrom ve schizofrenii: pøehled ................................................ 94
R. Rokyta: Bolest a její patofyziologie ................................................................ 103
J. Patočka, M. Tichý, D. Řípová, R. Jirák: Apolipoprotein E
jako rizikový faktor demence .............................................................................. 108
KAZUISTIKY
L. Motlová: Olanzapin v léèbì schizofrenie ........................................................... 112
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová antipsychotika II. generace: Olanzapin ....................................................... 115
ZPRÁVY ......................................................................................................... 124
Přečetli jsme za Vás ....................................................................................... 138
DOPISY, DISKUZE A OHLASY.......................................................................... 143
NOVÉ KNIHY.................................................................................................... 147
INFORMACE ................................................................................................... 149
EDITORIAL ....................................................................................................... 62
ORIGINAL PAPERS
J. Libiger, J. Švestka and the Czech team of study evaluators:
Olanzapine Versus Haloperidol: Acute Phase Results
of the Double Blind Randomized Clinical Study of Efficacy
of a New Atypical Antipsychotic in Patients with
Schizophrenia and Schizoaffective Psychosis ...................................................... 64
J. Židovská, Š. Růžičková, M. Vojtíšková, E. Havrdová, J. Roth, J. Kapras:
DNA analysis of the Huntington's Disease Gene
in the Czech Population ..................................................................................... 70
J. Bečka, E. Nagyová, J. Horáček:
Dream Characteristics in Selected Mental Disorders ............................................ 74
REVIEWS
C. Höschl: Theory of Depression ........................................................................ 78
M. Alda: What is New in Genetic Research of Bipolar Illness ................................ 86
P. Mohr: Deficit Syndrome of Schizophrenia: A Review ........................................ 94
R. Rokyta: Pain and its Pathophysiology ......................................................... 103
J. Patočka, M. Tichý, D. Řípová, R. Jirák: Apolipoprotein E
as a Risk Factor of Dementia ........................................................................... 108
CASE REPORTS
L. Motlová: Olanzapine in the Treatment of Schizophrenia .................................... 112
NEW PSYCHOTROPICS
J. Švestka:
New Antipsychotics of the 2nd generation: Olanzapine ....................................... 115
COMMUNICATIONS ........................................................................................ 124
We have read for you ....................................................................................... 138
CORRESPONDENCE, DISCUSSION................................................................. 143
NEW BOOKS ................................................................................................. 147
INFORMATION ............................................................................................... 149
EDITORIAL ......................................................................................................................... 2
PŘEHLEDNÉ ČLÁNKY
P. Petrovický:
Struktury a dráhy monoaminových systémů (noradrenalin, dopamin, serotonin) ........................ 4
K. Šonka:
Obstrukční spánkový apnoický syndrom ............................................................................. 12
S. Liptáková, L. Velíšek:
Katastrofické epilepsie dìtského vìku a jejich modely ........................................................... 18
R. Balon:
Výuka psychiatrie ve Spojených státech ............................................................................ 23
Z. Dytrych:
Nové sociální fenomény a duševní zdraví v ČR ................................................................... 28
KRÁTKÁ SDĚLENÍ........................................................................................................... 31
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová antidepresiva: Tianeptin, klinicko-farmakologický paradox ........................................... 32
ZPRÁVY ........................................................................................................................ 38
DOPISY, DISKUSE A OHLASY......................................................................................... 51
NOVÉ KNIHY ................................................................................................................. 53
INFORMACE.................................................................................................................. 59
Rejstříky
EDITORIAL ..................................................................................................................... 2
REVIEWS
P. Petrovický:
Structures and Pathways of Monoamine Systems (Noradrenaline, Dopamine, Serotonine) ..... 4
K. Šonka:
Obstructive Sleep Apnea Syndrome ................................................................................. 12
S. Liptáková, L. Velíšek:
Catastrophic Epilepsies of Childhood and their Models ...................................................... 18
R. Balon:
Teaching of Psychiatry in the United States ..................................................................... 23
Z. Dytrych:
New Social Phenomena and Mental Health in Czech Republic ........................................... 28
BRIEF ARTICLES .......................................................................................................... 31
NEW PSYCHOTROPICS
J. Švestka:
New Antidepressants: Tianeptine, the Clinical-Pharmacological Paradox ............................. 32
COMMUNICATIONS ...................................................................................................... 38
CORRESPONDENCE, DISCUSSION ............................................................................. 51
NEW BOOKS ............................................................................................................. 53
INFORMATION ........................................................................................................... 59
Index
Více...
PŮVODNÍ PRÁCE
J. Libiger
Klasifikace v nesnázích ..................................................................................................... 116
R. Balon
Quo Vadis DSM? .............................................................................................................. 123
P. Grof
Jak diagnostikovat bipolární poruchu: problémy, které přinesly studie s potomky ........................................................................................................................... 127
M. Alda
Charakterizuje odpověď na profylaxi lithiem specifický typ bipolární
poruchy? ......................................................................................................................... 131
J. Volavka
Schizofrenie a násilí ......................................................................................................... 137
J. Horáček
Vliv polymorfizmu genu RGS4 (Regulator of G-protein signaling 4) na
regionální metabolizmus mozku (18FDG PET) a fenotypové proměnné
u schizofrenie ................................................................................................................... 141
CONTENTS
EDITORIAL ....................................................................................................................... 114J. Libiger
Troubles of Psychiatric Classification .................................................................................. 116
J. Balon
Quo Vadis DSM? ............................................................................................................... 123
P. Grof
Diagnosing bipolar disorders: recent challenges from the studies
of offspring ........................................................................................................................ 127
M. Alda
Does response to prophylactic lithium characterize a distinct form of bipolar
disorder? ........................................................................................................................... 131
J. Volavka
Schizophrenia and violence .................................................................................................. 137
J. Horáček
The influence of polymorphism for gene RGS4 (Regulator of G-protein
signaling 4) on regional brain metabolism (18FDG PET) and phenotypic
variables in schizophrenia .................................................................................................... 141
PROGRAM .......................................................................................................................... 4
Středa 10. června ................................................................................................................. 4
Čtvrtek 11. června .................................................................................................................. 4
Pátek 12. června ................................................................................................................... 5
Sobota 13. června ................................................................................................................. 6
Postery ................................................................................................................................ 7
KRÁTKÁ SDĚLENÍ .............................................................................................................. 10
POSTERY ........................................................................................................................... 70
CONTENTS
EDITORIAL ........................................................................................................................... 1
PROGRAMME ...................................................................................................................... 4
Wednesday 10th June ............................................................................................................ 4
Thursday 11th June ................................................................................................................ 4
Friday 12th June .................................................................................................................... 5
Saturday 13th June ............................................................................................................... 6
Posters ................................................................................................................................ 7
SHORT COMMUNICATIONS ................................................................................................. 10
POSTERS ........................................................................................................................... 70
EDITORIAL ........................................................................................................................ 1 PROGRAM ........................................................................................................................ 4
PLENÁRNÍ PŘEDNÁŠKY .................................................................................................. 12
ODBORNÁ SYMPOZIA
ANTIPSYCHOTIKA
Představují antipsychotika a halucinogeny opačné strany téže mince? .................................. 14
Faktory ovlivňující volbu a efekt antipsychotik ....................................................................... 15
ANTIDEPRESIVA
Farmakoterapie deprese napříč diagnostickým spektrem ...................................................... 16
PERSONALIZOVANÁ FARMAKOTERAPIE I.
Psychofarmakogenetika ..................................................................................................... 18
Kontroverzní témata v hodnocení účinnosti psychofarmak ..................................................... 19
TERAPIE V NEUROPSYCHIATRII I.
Neuropsychiatrický profil a farmakoterapie onemocnění z okruhu
atypických parkinsonských syndromù ................................................................................. 20
Organické psychotické poruchy a možnosti jejich léèby ........................................................ 21
FARMAKOTERAPIE V PEDOPSYCHIATRII
Psychofarmaka v dětství a dospívání .................................................................................... 22
Aktuální otázky z pedopsychiatrické praxe ........................................................................... 23
TERAPIE V NEUROPSYCHIATRII II.
Farmakologické a invazivní terapeutické metody v neuropsychiatrii ......................................... 23
Neuronální mechanizmy „Systému odměny" ........................................................................ 24
FARMAKOTERAPIE V GERONTOPSYCHIATRII
Neurobiologie a psychofarmaka ve stáří ............................................................................... 26
Úzkostné poruchy ve vyšším vìku a jejich léčba .................................................................... 27
PERSONALIZOVANÁ FARMAKOTERAPIE II.
Predikce odpovědi na psychofarmaka .................................................................................. 28
Proč naši pacienti nechtějí brát léky a co s tím můžeme dělat ............................................... 29
SNÍDANĚ ČNPS
Cirkadiánní rytmicita: od vědy po praktické použití ................................................................ 30
Indikace psychofarmak podle pohlaví ................................................................................... 31
NOVÝ VÝZKUM
Nový výzkum I.: Preklinické studie ....................................................................................... 32
Nový výzkum II.: Od animálních studií k pacientovi.................................................................. 34
Nový výzkum III.: Klinické studie .......................................................................................... 35
WORKSHOPY
1. Psychogenní poruchy hybnosti ......................................................................................... 38
2. Umíme diagnostikovat a léčit autismus? ............................................................................ 38
3. Sedmero hlavních hříchů: Hněv .......................................................................................... 38
4. Jaká farmaka neužívat jako stabilizátory nálady? ................................................................ 39
5. Disociativní křeče ............................................................................................................ 40
6. Diferenciální diagnostika a farmakoterapie demencí ............................................................. 40
7. Optimalizace terapie afektivních a psychotických poruch ..................................................... 41
8. Psychózy 3. druhu: adekvátní diagnostika a léčba akutních psychotických poruch ................. 41
SETKÁNÍ S ODBORNÍKEM
Prof. Jan Volavka, MD, PhD .................................................................................................. 42
Prof. MUDr. Daniela Ježová, DrSc. ......................................................................................... 42
VÝVĚSKOVÁ SDĚLENÍ
Preklinický výzkum I. (stres, úzkost a neuroprotektivita) .......................................................... 43
Klinický výzkum I. (afektivní a úzkostné poruchy) .................................................................... 47
Preklinický výzkum II. (návykové látky a antipsychotika) .......................................................... 49
Klinický výzkum II. (psychózy a závislosti) ............................................................................. 52
Preklinický výzkum III. (kognitiva) ........................................................................................... 55
Klinický výzkum III. (problémové oblasti farmakoterapie) ........................................................... 58
FIREMNÍ SYMPOZIA ............................................................................................................ 61
REJSTŘÍK AUTORÙ ............................................................................................................. 62
CONTENTS
EDITORIAL ........................................................................................................................... 1 PROGRAMME ...................................................................................................................... 4
PLENARY LECTURES ......................................................................................................... 12
SCIENTIFIC SYMPOSIA
ANTIPSYCHOTICS
Are antipsychotics and hallucinogens opposite sides of the same coin? .................................... 14
Factors influencing choice and effect of antipsychotics ............................................................ 15
ANTIDEPRESSANTS
Pharmacotherapy of depression in different psychiatric conditions ............................................. 16
PERSONALIZED PHARMACOTHERAPY I.
Psychopharmacogenetics ...................................................................................................... 18
Controversies in evaluation of drug efficacy .............................................................................. 19
THERAPY IN NEUROPSYCHIATRY I.
Neuropsychiatric profile and pharmacotherapy of the atypical parkinsonian syndromes .......................................................................................................................... 20
Organic psychoses and possibilities of pharmacological treatment ........................................... 21
PHARMACOTHERAPY IN CHILD PSYCHIATRY
Child and adolescent psychopharmacology ............................................................................ 22
Current issues in child and adolescent psychiatric care ........................................................... 23
THERAPY IN NEUROPSYCHIATRY II.
Pharmacological and invasive methods in neuropsychiatry ....................................................... 23
Neuronal mechanisms of the „Reward system" ....................................................................... 24
PHARMACOTHERAPY IN GERIATRIC PSYCHIATRY
Neurobiology and psychotropics in the elderly ........................................................................ 26
Anxiety disorders in the elderly and their treatment ................................................................. 27
PERSONALIZED PHARMACOTHERAPY II.
Prediction of treatment response to psychotropic drugs ........................................................... 28
Why our patients do not want to take drugs and what we can do with it .................................... 29
ČNPS BREAKFAST SYMPOSIA
Circadian rhythms: From science to clinical application .......................................................... 30
Indication of psychotropic drugs based on gender .................................................................. 31
FREE COMMUNICATIONS – NEW RESEARCH
New Research I.: Preclinical studies ..................................................................................... 32
New Research II.: From animal studies to patients ................................................................. 34
New Research III.: Clinical studies ........................................................................................ 35
WORKSHOPS
1. Psychogenic movement disorders ..................................................................................... 38
2. Are we able to diagnose and to treat autism? ..................................................................... 38
3. Seven deadly sins – Anger ................................................................................................ 38
4. Which drugs should not be used as mood stabilizers? ......................................................... 39
5. Dissociative seizures ........................................................................................................ 40
6. Differential diagnosis and pharmacotherapy of dementia ...................................................... 40
7. Optimalization of treatment of affective and psychotic disorders ............................................ 41
8. Psychoses of the third kind: Diagnostics and treatment of acute psychotic disorders ............. 41
MEET THE EXPERT
Prof. Jan Volavka, MD, PhD. ................................................................................................. 42
Prof. MUDr. Daniela Ježová, DrSc. ......................................................................................... 42
POSTER SESSIONS
Preclinical Research I. (Stress, anxiety and neuroprotectivity) .................................................. 43
Clinical Research I. (Affective and anxiety disorders) ............................................................... 47
Prelinical Research II. (Addictive substances and antipsychotics) ............................................. 49
Clinical Research II. (Psychotic disorders and addiction) .......................................................... 52
Prelinical Research III. (Cognitive drugs) ................................................................................. 55
Clinical Research III. (Problems in pharmocotherapy) ............................................................... 58
INDUSTRY-SPONSORED SATELLITE SYMPOSIA ................................................................. 61
AUTHOR INDEX ................................................................................................................... 62
